

# Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

**Status:** RECRUITING

## Eligibility Criteria

**Age:** 21 years and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

### Inclusion Criteria:

All criteria need to be met. \* Acute ST segment elevation myocardial infarction defined as: \* chest pain, consistent with angina, within the prior 12 hours (for intermittent pain lasting more than 12 hours, the time from the when the pain became severe and constant); \* ST segment elevation on ECG  $\geq 1$  mm in 2 or more anatomically contiguous leads; \* Reperfusion strategy planned or completed (including percutaneous coronary intervention or fibrinolysis) \* Age  $\geq 21$  years.

### Exclusion Criteria:

Subjects will not be eligible if they meet any of the following exclusion criteria. \* Pregnancy; \* Inability to obtain consent from patient; \* History of prior STEMI or of systolic heart failure (LVEF $\leq 40\%$ ); \* Contraindications to treatment with anakinra (i.e. prior allergic reaction to Kineret® or E. coli derived products); \* Duration of chest pain  $\geq 12$  hours at time of coronary artery catheterization (continuously

•see exceptions in Inclusion Criteria) or coronary artery intervention  $\geq 12$  hours earlier (see exceptions in Inclusion Criteria) (max duration of chest pain 24 hours); \* Failed reperfusion strategy (unsuccessful percutaneous coronary intervention); \* Need or plan for emergent cardiac surgery; \* Anticipated inability to complete a cardiopulmonary exercise test (CPET) on a treadmill at follow up visit at 42 days (i.e. amputee, wheel-chair bound, severe non-cardiac illness limiting mobility). \* Active infection (such as acute, i.e. COVID-19, or chronic/recurrent infectious disease i.e. HBV, HCV, and HIV/AIDS-but excluding HCV+ patients with undetectable plasma RNA) \* Acute or chronic inflammatory disease or immunosuppressive therapies (including oral corticosteroids at a dose of prednisone equivalent of 0.5 mg/kg/day but not including inhaled or low dose oral corticosteroids or non-steroidal anti-inflammatory drugs). \* Neutropenia ( $< 1,500/\text{mm}^3$  or  $< 1,000/\text{mm}^3$  in African-American patients). \* Active acute or chronic psychiatric illness that in the opinion of the investigator may prevent from complying with study instructions; \* Stage V chronic kidney disease (estimated glomerular filtration rate 15 mL/min/1.73m<sup>2</sup> or less) or on renal-replacement therapy (a GFR  $\geq 45$  mL/min/1.73m<sup>2</sup> is required for the cardiac magnetic resonance portion of the study); \* Limited English Proficiency that in the opinion of the investigator may prevent from understanding the content of the informed consent form and instructions during the tests required for the study. \* Any comorbidity limiting survival or ability to complete the study.

## Conditions & Interventions

### Interventions:

DRUG: Anakinra, OTHER: Placebo

### Conditions:

Heart Failure

## More Information

**Contact(s):** Benjamin Van Tassell, PharmD - bvantassell@vcu.edu

**Principal Investigator:** Abbate, Antonio

**Phase:** PHASE2

**IRB**

**Number:** HM20022826

**System ID:** NCT05177822

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact [ctrrecruit@vcu.edu](mailto:ctrrecruit@vcu.edu) if you have questions or need assistance.